Research analysts at StockNews.com started coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI – Get Free Report) in a report released on Tuesday. The brokerage set a “hold” rating on the biotechnology company’s stock.
Brainstorm Cell Therapeutics Stock Down 0.6 %
NASDAQ BCLI opened at $1.58 on Tuesday. The stock has a market cap of $9.01 million, a P/E ratio of -0.33 and a beta of 0.74. The company’s 50-day simple moving average is $1.83 and its 200 day simple moving average is $2.18. Brainstorm Cell Therapeutics has a twelve month low of $1.05 and a twelve month high of $11.89.
Brainstorm Cell Therapeutics Company Profile
Featured Articles
- Five stocks we like better than Brainstorm Cell Therapeutics
- Conference Calls and Individual Investors
- Can TikTok Stock Picks Really Make You Rich?
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- The “Quality” Rotation: Back to Basics Investing
- Industrial Products Stocks Investing
- Occidental Petroleum: 4 Reasons to Love These Prices
Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.